Combines LifeArc’s translational expertise with the Milner’s cutting-edge bioinformatics
New £30 million translational partnership will accelerate development of new treatments for people with dementia
Funding will accelerate development of new diagnostic tests, treatments, and devices for people with dementia.
LifeArc scientists instrumental to the development of the world’s first anti-IL17BR antibody, now being trialled as a treatment for severe asthma
New, multi-million pound research programme at the University of Edinburgh will develop treatments for lung infections
Action Medical Research and LifeArc announce another round of funding to support translational research into children’s rare diseases
£1m fund to progress promising translational research addressing a medical need for children and young people
LifeArc co-founded company RQ Bio signs licensing agreement with AstraZeneca worth up to $157m plus royalties for monoclonal antibodies against SARS-CoV-2
AstraZeneca granted exclusive worldwide licence to develop, manufacture and commercialise RQ Bio’s existing early-stage monoclonal antibodies (mAbs)…
How can we reduce the impact of dementia on individuals, families and wider society?
Melanie Lee on how bringing together diverse teams united under a clear purpose can deliver extraordinary results.
Together with the patient charity Motor Neurone Disease (MND) Association, LifeArc co-sponsored an MND challenge within a…